Click for best price
Recombinant Protein Drugs Market Size, Share 2022
Market Analysis and Insights: Global Recombinant Protein Drugs Market
The global Recombinant Protein Drugs market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Recombinant Protein Drugs market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Recombinant Protein Drugs market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Recombinant Protein Drugs market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Recombinant Protein Drugs market.
Global Recombinant Protein Drugs Scope and Market Size
Recombinant Protein Drugs market is segmented by region (country), players, by Type and by Application. Players, stakeholders, and other participants in the global Recombinant Protein Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application for the period 2017-2028.
For United States market, this report focuses on the Recombinant Protein Drugs market size by players, by Type and by Application, for the period 2017-2028. The key players include the global and local players, which play important roles in United States.
Segment by Type
Recombinant DNA
Recombinant RNA
Segment by Application
Pharmaceutical Industry
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
By Company
Novo Nordisk
Amgen
Sanofi
Eli Lilly
Merck Serono
Ortho Biotech
Roche
Kyowa Hakko Kirin
Pharmingen
Abcam
GenSci
SL PHARM
Dongbao Pharm
Ankebio
NCPC
Heng Rui
The information for each competitor/Company Profile includes:
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
The content of the study subjects includes a total of 15 chapters:
Chapter 1, describes Recombinant Protein Drugs product scope, market overview, market opportunities, market driving force, and market risks.
Chapter 2, profiles the top manufacturers of Recombinant Protein Drugs, with price, sales, revenue, and global market share of Recombinant Protein Drugs from 2019 to 2022.
Chapter 3, the Recombinant Protein Drugs competitive situation, sales, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Recombinant Protein Drugs breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapters 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, and application, from 2017 to 2028.
Chapters 7, 8, 9, 10, and 11, to break the sales data at the country level, with sales, revenue, and market share for key countries in the world, from 2017 to 2022. and the Recombinant Protein Drugs market forecast, by regions, type, and application, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of Recombinant Protein Drugs.
Chapter 13, 14, and 15, to describe Recombinant Protein Drugs sales channel, distributors, customers, research findings and conclusion, appendix and data source.
Key Indicators Analysed:
- Market Players & Competitor Analysis: The report covers the key players of the industry including Company Profile, Product Specifications, Production Capacity/Sales, Revenue, Price and Gross Margin 2016-2027 & Sales with a thorough analysis of the market?s competitive landscape and detailed information on vendors and comprehensive details of factors that will challenge the growth of major market vendors.
- Global and Regional Market Analysis: The report includes Global & Regional market status and outlook 2016-2027. Further the report provides break down details about each region & countries covered in the report. Identifying its sales, sales volume & revenue forecast. With detailed analysis by types and applications.
- Market Trends: Market key trends which include Increased Competition and Continuous Innovations.
- Opportunities and Drivers: Identifying the Growing Demands and New Technology
- Porters Five Force Analysis: The report provides with the state of competition in industry depending on five basic forces: threat of new entrants, bargaining power of suppliers, bargaining power of buyers, threat of substitute products or services, and existing industry rivalry.
Reasons to Purchase this Report:
- Estimates 2022-2027 2021-2025 Recombinant Protein Drugs Report on, Status and Forecast, by Players, Types and Applications market development trends with the recent trends and SWOT analysis
- Market dynamics scenario, along with growth opportunities of the market in the years to come
- Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects
- Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
- Market value (USD Million) and volume (Units Million) data for each segment and sub-segment
- Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
- Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players
- 1-year analyst support, along with the data support in excel format.
Research Methodology:
The research methodology used to estimate and forecast this market begins by capturing the revenues of the key players and their shares in the market. Various secondary sources such as press releases, annual reports, non-profit organizations, industry associations, governmental agencies and customs data, have been used to identify and collect information useful for this extensive commercial study of the market. Calculations based on this led to the overall market size. After arriving at the overall market size, the total market has been split into several segments and subsegments, which have then been verified through primary research by conducting extensive interviews with industry experts such as CEOs, VPs, directors, and executives. The data triangulation and market breakdown procedures have been employed to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments.
| Report Attributes |
Report Details |
| Report Title |
Global and United States Recombinant Protein Drugs Market Report & Forecast 2022-2028 |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2021 |
| Forecast Year |
2029 |
| Number of Pages |
114 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
1 Study Coverage
1.1 Recombinant Protein Drugs Product Introduction
1.2 Global Recombinant Protein Drugs Outlook 2017 VS 2022 VS 2028
1.2.1 Global Recombinant Protein Drugs Sales in US$ Million for the Year 2017-2028
1.2.2 Global Recombinant Protein Drugs Sales in Volume for the Year 2017-2028
1.3 United States Recombinant Protein Drugs Outlook 2017 VS 2022 VS 2028
1.3.1 United States Recombinant Protein Drugs Sales in US$ Million for the Year 2017-2028
1.3.2 United States Recombinant Protein Drugs Sales in Volume for the Year 2017-2028
1.4 Recombinant Protein Drugs Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.4.1 The Market Share of United States Recombinant Protein Drugs in Global, 2017 VS 2022 VS 2028
1.4.2 The Growth Rate of Recombinant Protein Drugs Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.5 Recombinant Protein Drugs Market Dynamics
1.5.1 Recombinant Protein Drugs Industry Trends
1.5.2 Recombinant Protein Drugs Market Drivers
1.5.3 Recombinant Protein Drugs Market Challenges
1.5.4 Recombinant Protein Drugs Market Restraints
1.6 Study Objectives
1.7 Years Considered
2 Market by Type
2.1 Recombinant Protein Drugs Market Segment by Type
2.1.1 Recombinant DNA
2.1.2 Recombinant RNA
2.2 Global Recombinant Protein Drugs Market Size by Type
2.2.1 Global Recombinant Protein Drugs Sales in Value, by Type (2017, 2022 & 2028)
2.2.2 Global Recombinant Protein Drugs Sales in Volume, by Type (2017, 2022 & 2028)
2.2.3 Global Recombinant Protein Drugs Average Selling Price (ASP) by Type (2017, 2022 & 2028)
2.3 United States Recombinant Protein Drugs Market Size by Type
2.3.1 United States Recombinant Protein Drugs Sales in Value, by Type (2017, 2022 & 2028)
2.3.2 United States Recombinant Protein Drugs Sales in Volume, by Type (2017, 2022 & 2028)
2.3.3 United States Recombinant Protein Drugs Average Selling Price (ASP) by Type (2017, 2022 & 2028)
3 Market by Application
3.1 Recombinant Protein Drugs Market Segment by Application
3.1.1 Pharmaceutical Industry
3.1.2 Others
3.2 Global Recombinant Protein Drugs Market Size by Application
3.2.1 Global Recombinant Protein Drugs Sales in Value, by Application (2017, 2022 & 2028)
3.2.2 Global Recombinant Protein Drugs Sales in Volume, by Application (2017, 2022 & 2028)
3.3.3 Global Recombinant Protein Drugs Average Selling Price (ASP) by Application (2017, 2022 & 2028)
3.3 United States Recombinant Protein Drugs Market Size by Application
3.3.1 United States Recombinant Protein Drugs Sales in Value, by Application (2017, 2022 & 2028)
3.3.2 United States Recombinant Protein Drugs Sales in Volume, by Application (2017, 2022 & 2028)
3.3.3 United States Recombinant Protein Drugs Average Selling Price (ASP) by Application (2017, 2022 & 2028)
4 Global Recombinant Protein Drugs Competitor Landscape by Company
4.1 Global Recombinant Protein Drugs Market Size by Company
4.1.1 Top Global Recombinant Protein Drugs Manufacturers Ranked by Revenue (2021)
4.1.2 Global Recombinant Protein Drugs Revenue by Manufacturer (2017-2022)
4.1.3 Global Recombinant Protein Drugs Sales by Manufacturer (2017-2022)
4.1.4 Global Recombinant Protein Drugs Price by Manufacturer (2017-2022)
4.2 Global Recombinant Protein Drugs Concentration Ratio (CR)
4.2.1 Recombinant Protein Drugs Market Concentration Ratio (CR) (2017-2022)
4.2.2 Global Top 5 and Top 10 Largest Manufacturers of Recombinant Protein Drugs in 2021
4.2.3 Global Recombinant Protein Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.3 Global Recombinant Protein Drugs Manufacturing Base Distribution, Product Type
4.3.1 Global Recombinant Protein Drugs Manufacturers, Headquarters and Distribution of Producing Region
4.3.2 Manufacturers Recombinant Protein Drugs Product Type
4.3.3 Date of International Manufacturers Enter into Recombinant Protein Drugs Market
4.4 Manufacturers Mergers & Acquisitions, Expansion Plans
4.5 United States Recombinant Protein Drugs Market Size by Company
4.5.1 Top Recombinant Protein Drugs Players in United States, Ranked by Revenue (2021)
4.5.2 United States Recombinant Protein Drugs Revenue by Players (2020, 2021 & 2022)
4.5.3 United States Recombinant Protein Drugs Sales by Players (2020, 2021 & 2022)
5 Global Recombinant Protein Drugs Market Size by Region
5.1 Global Recombinant Protein Drugs Market Size by Region: 2017 VS 2022 VS 2028
5.2 Global Recombinant Protein Drugs Market Size in Volume by Region (2017-2028)
5.2.1 Global Recombinant Protein Drugs Sales in Volume by Region: 2017-2022
5.2.2 Global Recombinant Protein Drugs Sales in Volume Forecast by Region (2023-2028)
5.3 Global Recombinant Protein Drugs Market Size in Value by Region (2017-2028)
5.3.1 Global Recombinant Protein Drugs Sales in Value by Region: 2017-2022
5.3.2 Global Recombinant Protein Drugs Sales in Value by Region: 2023-2028
6 Segment in Region Level & Country Level
6.1 North America
6.1.1 North America Recombinant Protein Drugs Market Size YoY Growth 2017-2028
6.1.2 North America Recombinant Protein Drugs Market Facts & Figures by Country (2017, 2022 & 2028)
6.1.3 U.S.
6.1.4 Canada
6.2 Asia-Pacific
6.2.1 Asia-Pacific Recombinant Protein Drugs Market Size YoY Growth 2017-2028
6.2.2 Asia-Pacific Recombinant Protein Drugs Market Facts & Figures by Region (2017, 2022 & 2028)
6.2.3 China
6.2.4 Japan
6.2.5 South Korea
6.2.6 India
6.2.7 Australia
6.2.8 Taiwan
6.2.9 Indonesia
6.2.10 Thailand
6.2.11 Malaysia
6.2.12 Philippines
6.3 Europe
6.3.1 Europe Recombinant Protein Drugs Market Size YoY Growth 2017-2028
6.3.2 Europe Recombinant Protein Drugs Market Facts & Figures by Country (2017, 2022 & 2028)
6.3.3 Germany
6.3.4 France
6.3.5 U.K.
6.3.6 Italy
6.3.7 Russia
6.4 Latin America
6.4.1 Latin America Recombinant Protein Drugs Market Size YoY Growth 2017-2028
6.4.2 Latin America Recombinant Protein Drugs Market Facts & Figures by Country (2017, 2022 & 2028)
6.4.3 Mexico
6.4.4 Brazil
6.4.5 Argentina
6.5 Middle East and Africa
6.5.1 Middle East and Africa Recombinant Protein Drugs Market Size YoY Growth 2017-2028
6.5.2 Middle East and Africa Recombinant Protein Drugs Market Facts & Figures by Country (2017, 2022 & 2028)
6.5.3 Turkey
6.5.4 Saudi Arabia
6.5.5 U.A.E
7 Company Profiles
7.1 Novo Nordisk
7.1.1 Novo Nordisk Corporation Information
7.1.2 Novo Nordisk Description and Business Overview
7.1.3 Novo Nordisk Recombinant Protein Drugs Sales, Revenue and Gross Margin (2017-2022)
7.1.4 Novo Nordisk Recombinant Protein Drugs Products Offered
7.1.5 Novo Nordisk Recent Development
7.2 Amgen
7.2.1 Amgen Corporation Information
7.2.2 Amgen Description and Business Overview
7.2.3 Amgen Recombinant Protein Drugs Sales, Revenue and Gross Margin (2017-2022)
7.2.4 Amgen Recombinant Protein Drugs Products Offered
7.2.5 Amgen Recent Development
7.3 Sanofi
7.3.1 Sanofi Corporation Information
7.3.2 Sanofi Description and Business Overview
7.3.3 Sanofi Recombinant Protein Drugs Sales, Revenue and Gross Margin (2017-2022)
7.3.4 Sanofi Recombinant Protein Drugs Products Offered
7.3.5 Sanofi Recent Development
7.4 Eli Lilly
7.4.1 Eli Lilly Corporation Information
7.4.2 Eli Lilly Description and Business Overview
7.4.3 Eli Lilly Recombinant Protein Drugs Sales, Revenue and Gross Margin (2017-2022)
7.4.4 Eli Lilly Recombinant Protein Drugs Products Offered
7.4.5 Eli Lilly Recent Development
7.5 Merck Serono
7.5.1 Merck Serono Corporation Information
7.5.2 Merck Serono Description and Business Overview
7.5.3 Merck Serono Recombinant Protein Drugs Sales, Revenue and Gross Margin (2017-2022)
7.5.4 Merck Serono Recombinant Protein Drugs Products Offered
7.5.5 Merck Serono Recent Development
7.6 Ortho Biotech
7.6.1 Ortho Biotech Corporation Information
7.6.2 Ortho Biotech Description and Business Overview
7.6.3 Ortho Biotech Recombinant Protein Drugs Sales, Revenue and Gross Margin (2017-2022)
7.6.4 Ortho Biotech Recombinant Protein Drugs Products Offered
7.6.5 Ortho Biotech Recent Development
7.7 Roche
7.7.1 Roche Corporation Information
7.7.2 Roche Description and Business Overview
7.7.3 Roche Recombinant Protein Drugs Sales, Revenue and Gross Margin (2017-2022)
7.7.4 Roche Recombinant Protein Drugs Products Offered
7.7.5 Roche Recent Development
7.8 Kyowa Hakko Kirin
7.8.1 Kyowa Hakko Kirin Corporation Information
7.8.2 Kyowa Hakko Kirin Description and Business Overview
7.8.3 Kyowa Hakko Kirin Recombinant Protein Drugs Sales, Revenue and Gross Margin (2017-2022)
7.8.4 Kyowa Hakko Kirin Recombinant Protein Drugs Products Offered
7.8.5 Kyowa Hakko Kirin Recent Development
7.9 Pharmingen
7.9.1 Pharmingen Corporation Information
7.9.2 Pharmingen Description and Business Overview
7.9.3 Pharmingen Recombinant Protein Drugs Sales, Revenue and Gross Margin (2017-2022)
7.9.4 Pharmingen Recombinant Protein Drugs Products Offered
7.9.5 Pharmingen Recent Development
7.10 Abcam
7.10.1 Abcam Corporation Information
7.10.2 Abcam Description and Business Overview
7.10.3 Abcam Recombinant Protein Drugs Sales, Revenue and Gross Margin (2017-2022)
7.10.4 Abcam Recombinant Protein Drugs Products Offered
7.10.5 Abcam Recent Development
7.11 GenSci
7.11.1 GenSci Corporation Information
7.11.2 GenSci Description and Business Overview
7.11.3 GenSci Recombinant Protein Drugs Sales, Revenue and Gross Margin (2017-2022)
7.11.4 GenSci Recombinant Protein Drugs Products Offered
7.11.5 GenSci Recent Development
7.12 SL PHARM
7.12.1 SL PHARM Corporation Information
7.12.2 SL PHARM Description and Business Overview
7.12.3 SL PHARM Recombinant Protein Drugs Sales, Revenue and Gross Margin (2017-2022)
7.12.4 SL PHARM Products Offered
7.12.5 SL PHARM Recent Development
7.13 Dongbao Pharm
7.13.1 Dongbao Pharm Corporation Information
7.13.2 Dongbao Pharm Description and Business Overview
7.13.3 Dongbao Pharm Recombinant Protein Drugs Sales, Revenue and Gross Margin (2017-2022)
7.13.4 Dongbao Pharm Products Offered
7.13.5 Dongbao Pharm Recent Development
7.14 Ankebio
7.14.1 Ankebio Corporation Information
7.14.2 Ankebio Description and Business Overview
7.14.3 Ankebio Recombinant Protein Drugs Sales, Revenue and Gross Margin (2017-2022)
7.14.4 Ankebio Products Offered
7.14.5 Ankebio Recent Development
7.15 NCPC
7.15.1 NCPC Corporation Information
7.15.2 NCPC Description and Business Overview
7.15.3 NCPC Recombinant Protein Drugs Sales, Revenue and Gross Margin (2017-2022)
7.15.4 NCPC Products Offered
7.15.5 NCPC Recent Development
7.16 Heng Rui
7.16.1 Heng Rui Corporation Information
7.16.2 Heng Rui Description and Business Overview
7.16.3 Heng Rui Recombinant Protein Drugs Sales, Revenue and Gross Margin (2017-2022)
7.16.4 Heng Rui Products Offered
7.16.5 Heng Rui Recent Development
8 Industry Chain and Sales Channels Analysis
8.1 Recombinant Protein Drugs Industry Chain Analysis
8.2 Recombinant Protein Drugs Key Raw Materials
8.2.1 Key Raw Materials
8.2.2 Recombinant Protein Drugs Distributors
8.3 Recombinant Protein Drugs Production Mode & Process
8.4 Recombinant Protein Drugs Sales and Marketing
8.4.1 Recombinant Protein Drugs Sales Channels
8.4.2 Recombinant Protein Drugs Distributors
8.5 Recombinant Protein Drugs Customers
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Recombinant Protein Drugs CAGR in Value, United States VS Global, 2017 VS 2022 VS 2028
Table 2. Recombinant Protein Drugs Market Trends
Table 3. Recombinant Protein Drugs Market Drivers
Table 4. Recombinant Protein Drugs Market Challenges
Table 5. Recombinant Protein Drugs Market Restraints
Table 6. Global Recombinant Protein Drugs Sales by Type: 2017 VS 2022 VS 2028 (US$ Million)
Table 7. United States Recombinant Protein Drugs Sales by Type: 2017 VS 2022 VS 2028 (US$ Million)
Table 8. Global Recombinant Protein Drugs Sales by Application: 2017 VS 2022 VS 2028 (US$ Million)
Table 9. United States Recombinant Protein Drugs Sales by Application: 2017 VS 2022 VS 2028 (US$ Million)
Table 10. Top Recombinant Protein Drugs Manufacturers in Global Market, Ranking by Revenue (2021)
Table 11. Global Recombinant Protein Drugs Revenue by Manufacturer, (US$ Million), 2017-2022
Table 12. Global Recombinant Protein Drugs Revenue Share by Manufacturer, 2017-2022
Table 13. Global Recombinant Protein Drugs Sales by Manufacturer, (K Doses), 2017-2022
Table 14. Global Recombinant Protein Drugs Sales Share by Manufacturer, 2017-2022
Table 15. Global Recombinant Protein Drugs Price by Manufacturer (2017-2022) & (USD/Dose)
Table 16. Global Recombinant Protein Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 17. Global Recombinant Protein Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Recombinant Protein Drugs as of 2021)
Table 18. Top Players of Recombinant Protein Drugs in Global Market, Headquarters and Distribution of Producing Region
Table 19. Manufacturers Recombinant Protein Drugs Product Type
Table 20. Date of International Manufacturers Enter into Recombinant Protein Drugs Market
Table 21. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 22. Top Recombinant Protein Drugs Players in United States Market, Ranking by Revenue (2021)
Table 23. United States Recombinant Protein Drugs Revenue by Players, (US$ Million), 2020, 2021 & 2022
Table 24. United States Recombinant Protein Drugs Revenue Share by Players, 2020, 2021 & 2022
Table 25. United States Recombinant Protein Drugs Sales by Players, (K Doses), 2020, 2021 & 2022
Table 26. United States Recombinant Protein Drugs Sales Share by Players, 2020, 2021 & 2022
Table 27. Global Recombinant Protein Drugs Market Size by Region (US$ Million): 2017 VS 2022 VS 2028
Table 28. Global Recombinant Protein Drugs Sales in Volume by Region (2017-2022) & (K Doses)
Table 29. Global Recombinant Protein Drugs Sales in Volume Forecast by Region (2023-2028) & (K Doses)
Table 30. Global Recombinant Protein Drugs Sales in Value by Region (2017-2022) & (US$ Million)
Table 31. Global Recombinant Protein Drugs Sales in Value Forecast by Region (2023-2028) & (US$ Million)
Table 32. North America Recombinant Protein Drugs Sales in Volume by Country (2017-2028) & (K Doses)
Table 33. North America Recombinant Protein Drugs Sales in Value by Country (2017-2028) & (US$ Million)
Table 34. Asia Pacific Recombinant Protein Drugs Sales in Volume by Region (2017-2028) & (K Doses)
Table 35. Asia Pacific Recombinant Protein Drugs Sales in Value by Region (2017-2028) & (US$ Million)
Table 36. Europe Recombinant Protein Drugs Sales in Volume by Country (2017-2028) & (K Doses)
Table 37. Europe Recombinant Protein Drugs Sales in Value by Country (2017-2028) & (US$ Million)
Table 38. Latin America Recombinant Protein Drugs Sales in Volume by Country (2017-2028) & (K Doses)
Table 39. Latin Americaa Recombinant Protein Drugs Sales in Value by Country (2017-2028) & (US$ Million)
Table 40. Middle East and Africa Recombinant Protein Drugs Sales in Volume by Country (2017-2028) & (K Doses)
Table 41. Middle East and Africa Recombinant Protein Drugs Sales in Value by Country (2017-2028) & (US$ Million)
Table 42. Novo Nordisk Corporation Information
Table 43. Novo Nordisk Description and Business Overview
Table 44. Novo Nordisk Recombinant Protein Drugs Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 45. Novo Nordisk Recombinant Protein Drugs Product
Table 46. Novo Nordisk Recent Development
Table 47. Amgen Corporation Information
Table 48. Amgen Description and Business Overview
Table 49. Amgen Recombinant Protein Drugs Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 50. Amgen Product
Table 51. Amgen Recent Development
Table 52. Sanofi Corporation Information
Table 53. Sanofi Description and Business Overview
Table 54. Sanofi Recombinant Protein Drugs Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 55. Sanofi Product
Table 56. Sanofi Recent Development
Table 57. Eli Lilly Corporation Information
Table 58. Eli Lilly Description and Business Overview
Table 59. Eli Lilly Recombinant Protein Drugs Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 60. Eli Lilly Product
Table 61. Eli Lilly Recent Development
Table 62. Merck Serono Corporation Information
Table 63. Merck Serono Description and Business Overview
Table 64. Merck Serono Recombinant Protein Drugs Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 65. Merck Serono Product
Table 66. Merck Serono Recent Development
Table 67. Ortho Biotech Corporation Information
Table 68. Ortho Biotech Description and Business Overview
Table 69. Ortho Biotech Recombinant Protein Drugs Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 70. Ortho Biotech Product
Table 71. Ortho Biotech Recent Development
Table 72. Roche Corporation Information
Table 73. Roche Description and Business Overview
Table 74. Roche Recombinant Protein Drugs Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 75. Roche Product
Table 76. Roche Recent Development
Table 77. Kyowa Hakko Kirin Corporation Information
Table 78. Kyowa Hakko Kirin Description and Business Overview
Table 79. Kyowa Hakko Kirin Recombinant Protein Drugs Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 80. Kyowa Hakko Kirin Product
Table 81. Kyowa Hakko Kirin Recent Development
Table 82. Pharmingen Corporation Information
Table 83. Pharmingen Description and Business Overview
Table 84. Pharmingen Recombinant Protein Drugs Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 85. Pharmingen Product
Table 86. Pharmingen Recent Development
Table 87. Abcam Corporation Information
Table 88. Abcam Description and Business Overview
Table 89. Abcam Recombinant Protein Drugs Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 90. Abcam Product
Table 91. Abcam Recent Development
Table 92. GenSci Corporation Information
Table 93. GenSci Description and Business Overview
Table 94. GenSci Recombinant Protein Drugs Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 95. GenSci Product
Table 96. GenSci Recent Development
Table 97. SL PHARM Corporation Information
Table 98. SL PHARM Description and Business Overview
Table 99. SL PHARM Recombinant Protein Drugs Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 100. SL PHARM Product
Table 101. SL PHARM Recent Development
Table 102. Dongbao Pharm Corporation Information
Table 103. Dongbao Pharm Description and Business Overview
Table 104. Dongbao Pharm Recombinant Protein Drugs Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 105. Dongbao Pharm Product
Table 106. Dongbao Pharm Recent Development
Table 107. Ankebio Corporation Information
Table 108. Ankebio Description and Business Overview
Table 109. Ankebio Recombinant Protein Drugs Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 110. Ankebio Product
Table 111. Ankebio Recent Development
Table 112. NCPC Corporation Information
Table 113. NCPC Description and Business Overview
Table 114. NCPC Recombinant Protein Drugs Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 115. NCPC Product
Table 116. NCPC Recent Development
Table 117. Heng Rui Corporation Information
Table 118. Heng Rui Description and Business Overview
Table 119. Heng Rui Recombinant Protein Drugs Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 120. Heng Rui Product
Table 121. Heng Rui Recent Development
Table 122. Key Raw Materials Lists
Table 123. Raw Materials Key Suppliers Lists
Table 124. Recombinant Protein Drugs Customers List
Table 125. Recombinant Protein Drugs Distributors List
Table 126. Research Programs/Design for This Report
Table 127. Key Data Information from Secondary Sources
Table 128. Key Data Information from Primary Sources
List of Figures
Figure 1. Recombinant Protein Drugs Product Picture
Figure 2. Global Recombinant Protein Drugs Revenue, (US$ Million), 2017 VS 2022 VS 2028
Figure 3. Global Recombinant Protein Drugs Market Size 2017-2028 (US$ Million)
Figure 4. Global Recombinant Protein Drugs Sales 2017-2028 (K Doses)
Figure 5. United States Recombinant Protein Drugs Revenue, (US$ Million), 2017 VS 2022 VS 2028
Figure 6. United States Recombinant Protein Drugs Market Size 2017-2028 (US$ Million)
Figure 7. United States Recombinant Protein Drugs Sales 2017-2028 (K Doses)
Figure 8. United States Recombinant Protein Drugs Market Share in Global, in Value (US$ Million) 2017-2028
Figure 9. United States Recombinant Protein Drugs Market Share in Global, in Volume (K Doses) 2017-2028
Figure 10. Recombinant Protein Drugs Report Years Considered
Figure 11. Product Picture of Recombinant DNA
Figure 12. Product Picture of Recombinant RNA
Figure 13. Global Recombinant Protein Drugs Market Share by Type in 2022 & 2028
Figure 14. Global Recombinant Protein Drugs Sales in Value by Type (2017-2028) & (US$ Million)
Figure 15. Global Recombinant Protein Drugs Sales Market Share in Value by Type (2017-2028)
Figure 16. Global Recombinant Protein Drugs Sales by Type (2017-2028) & (K Doses)
Figure 17. Global Recombinant Protein Drugs Sales Market Share in Volume by Type (2017-2028)
Figure 18. Global Recombinant Protein Drugs Price by Type (2017-2028) & (USD/Dose)
Figure 19. United States Recombinant Protein Drugs Market Share by Type in 2022 & 2028
Figure 20. United States Recombinant Protein Drugs Sales in Value by Type (2017-2028) & (US$ Million)
Figure 21. United States Recombinant Protein Drugs Sales Market Share in Value by Type (2017-2028)
Figure 22. United States Recombinant Protein Drugs Sales by Type (2017-2028) & (K Doses)
Figure 23. United States Recombinant Protein Drugs Sales Market Share in Volume by Type (2017-2028)
Figure 24. United States Recombinant Protein Drugs Price by Type (2017-2028) & (USD/Dose)
Figure 25. Product Picture of Pharmaceutical Industry
Figure 26. Product Picture of Others
Figure 27. Global Recombinant Protein Drugs Market Share by Application in 2022 & 2028
Figure 28. Global Recombinant Protein Drugs Sales in Value by Application (2017-2028) & (US$ Million)
Figure 29. Global Recombinant Protein Drugs Sales Market Share in Value by Application (2017-2028)
Figure 30. Global Recombinant Protein Drugs Sales by Application (2017-2028) & (K Doses)
Figure 31. Global Recombinant Protein Drugs Sales Market Share in Volume by Application (2017-2028)
Figure 32. Global Recombinant Protein Drugs Price by Application (2017-2028) & (USD/Dose)
Figure 33. United States Recombinant Protein Drugs Market Share by Application in 2022 & 2028
Figure 34. United States Recombinant Protein Drugs Sales in Value by Application (2017-2028) & (US$ Million)
Figure 35. United States Recombinant Protein Drugs Sales Market Share in Value by Application (2017-2028)
Figure 36. United States Recombinant Protein Drugs Sales by Application (2017-2028) & (K Doses)
Figure 37. United States Recombinant Protein Drugs Sales Market Share in Volume by Application (2017-2028)
Figure 38. United States Recombinant Protein Drugs Price by Application (2017-2028) & (USD/Dose)
Figure 39. North America Recombinant Protein Drugs Sales in Volume Growth Rate 2017-2028 (K Doses)
Figure 40. North America Recombinant Protein Drugs Sales in Value Growth Rate 2017-2028 (US$ Million)
Figure 41. U.S. Recombinant Protein Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 42. Canada Recombinant Protein Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 43. Europe Recombinant Protein Drugs Sales in Volume Growth Rate 2017-2028 (K Doses)
Figure 44. Europe Recombinant Protein Drugs Sales in Value Growth Rate 2017-2028 (US$ Million)
Figure 45. Germany Recombinant Protein Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 46. France Recombinant Protein Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 47. U.K. Recombinant Protein Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 48. Italy Recombinant Protein Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 49. Russia Recombinant Protein Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 50. Asia-Pacific Recombinant Protein Drugs Sales in Volume Growth Rate 2017-2028 (K Doses)
Figure 51. Asia-Pacific Recombinant Protein Drugs Sales in Value Growth Rate 2017-2028 (US$ Million)
Figure 52. China Recombinant Protein Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 53. Japan Recombinant Protein Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 54. South Korea Recombinant Protein Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 55. India Recombinant Protein Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 56. Australia Recombinant Protein Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 57. Taiwan Recombinant Protein Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 58. Indonesia Recombinant Protein Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 59. Thailand Recombinant Protein Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 60. Malaysia Recombinant Protein Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 61. Philippines Recombinant Protein Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 62. Latin America Recombinant Protein Drugs Sales in Volume Growth Rate 2017-2028 (K Doses)
Figure 63. Latin America Recombinant Protein Drugs Sales in Value Growth Rate 2017-2028 (US$ Million)
Figure 64. Mexico Recombinant Protein Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 65. Brazil Recombinant Protein Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 66. Argentina Recombinant Protein Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 67. Middle East & Africa Recombinant Protein Drugs Sales in Volume Growth Rate 2017-2028 (K Doses)
Figure 68. Middle East & Africa Recombinant Protein Drugs Sales in Value Growth Rate 2017-2028 (US$ Million)
Figure 69. Turkey Recombinant Protein Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 70. Saudi Arabia Recombinant Protein Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 71. U.A.E Recombinant Protein Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 72. Recombinant Protein Drugs Value Chain
Figure 73. Recombinant Protein Drugs Production Process
Figure 74. Channels of Distribution
Figure 75. Distributors Profiles
Figure 76. Bottom-up and Top-down Approaches for This Report
Figure 77. Data Triangulation
Figure 78. Key Executives Interviewed
